Market Insights Health Pharmaceuticals Vaccines

Other Vaccines - Romania

Romania

In Romania, the revenue in the Other Vaccines market is projected to reach US$73.83m in 2024.
It is expected to show an annual growth rate (CAGR 2024-2029) of 10.64%, resulting in a market volume of US$122.40m by 2029.
When comparing globally, United States is anticipated to generate the most revenue in this market, with US$24,730.00m in 2024.
Romania has seen an increased demand for other vaccines, driven by a growing awareness of the importance of preventive healthcare among its population.

Key regions: Australia, Brazil, United Kingdom, Europe, Canada

Market

Region

Region comparison

Currency

Analyst Opinion

The Other Vaccines market in Romania has been experiencing steady growth in recent years.

Customer preferences: Romania has a high rate of vaccination coverage, which has contributed to the growth of the Other Vaccines market. Customers in Romania are becoming more aware of the importance of vaccination and are willing to take preventive measures against diseases.

Trends in the market: The Other Vaccines market in Romania has been growing due to the increasing demand for vaccines against various diseases such as meningococcal, pneumococcal, and rotavirus infections. The market has also seen an increase in the number of adults seeking vaccination against diseases such as influenza.

Local special circumstances: Romania has a large population of children, which has contributed to the growth of the Other Vaccines market. The country has also experienced outbreaks of vaccine-preventable diseases in recent years, which has increased awareness of the importance of vaccination.

Underlying macroeconomic factors: Romania has a growing economy, which has contributed to the growth of the Other Vaccines market. The government has also been investing in the healthcare sector, which has led to an increase in the availability of vaccines. Additionally, Romania is a member of the European Union, which has led to the adoption of EU vaccination guidelines and regulations.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.